Tailoring Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
BACKGROUND Research into chronic myeloid leukemia (CML) is increasingly focused on the problem of imatinib failure. Dasatinib and nilotinib are both active in chronic- and accelerated-phase CML, including patients with imatinib-resistant or intolerant disease. METHODS This paper reviews advances in tailoring tyrosine kinase inhibition therapy according to patient risk profiles as well as hema...
متن کاملTyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI granted regulatory approval, has been surpassed in terms of molecular responses by the second-generation TKIs nilotinib, dasatinib, and bosutinib. Recently, ponatinib was approved as the only TKI with activity agains...
متن کاملTyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-...
متن کاملUnfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
Dna2 was first characterized in yeast as an essential gene encoding a protein with both helicase and endonuclease activities involved in maturation of Okazaki fragments during DNA replication. Dna2 also plays a role in double-strand break (DSB) repair by homolo-gous recombination. The respective contributions of its replication and/or repair functions toward cell viability and resistance to gen...
متن کاملLong-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
With the success of tyrosine kinase inhibitor (TKI) therapy for the treatment of patients with chronic myeloid leukemia (CML), CML is now treated as a chronic disease. As such, the community of oncologists may see patients with CML more often than the primary-care physician and must focus on long-term management of adverse events and adherence. BCR-ABL1 TKIs are effective therapies in CML but a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Control
سال: 2009
ISSN: 1073-2748,1073-2748
DOI: 10.1177/107327480901600203